Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares shot up 6.8% during trading on Tuesday . The stock traded as high as $8.00 and last traded at $7.98. 151,993 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,471,363 shares. The stock had previously closed at $7.47.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on DYN shares. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. HC Wainwright restated a "buy" rating and issued a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, Piper Sandler decreased their price objective on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $47.46.
Read Our Latest Analysis on DYN
Dyne Therapeutics Stock Performance
The firm has a market cap of $924.20 million, a P/E ratio of -2.29 and a beta of 1.21. The stock's 50-day moving average is $11.14 and its 200 day moving average is $20.40.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.
Insider Buying and Selling
In related news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 6,237 shares of company stock worth $77,760 over the last ninety days. Company insiders own 20.77% of the company's stock.
Hedge Funds Weigh In On Dyne Therapeutics
Hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics in the fourth quarter valued at $50,000. KBC Group NV increased its position in shares of Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the last quarter. Neo Ivy Capital Management bought a new position in Dyne Therapeutics in the fourth quarter valued at approximately $205,000. Finally, GAMMA Investing LLC increased its position in shares of Dyne Therapeutics by 837.5% during the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after purchasing an additional 2,345 shares during the last quarter. 96.68% of the stock is owned by institutional investors.
About Dyne Therapeutics
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Further Reading
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
